EMA adds warning label to Novartis’ MS treatment Gilenya
December 22, 2015Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya
Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …
Pharma industry will pay £550m of NHS 2016 drugs bill
December 22, 2015Manufacturing and Production ABPI, PPRS, Pharmaceutical Price Regulation Scheme
A new financial agreement announced this week as part of the Pharmaceutical Price Regulation Scheme (PPRS), will see the pharmaceutical …
Sun Pharma hit by FDA inspection warning
December 22, 2015Manufacturing and Production FDA, Sun Pharma, manufacturing, production
Sun Pharma shares fell some 7% early this week after it emerged the Indian company received a warning letter from …
Former Cubist chief executive Michael Bonney to chair board at Alnylam
December 22, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alnylam, David Pyott, michael bonney
Michael Bonney, current board member and former chief executive of Cubist Pharmaceuticals, has been appointed as chairman of Alnylam Pharmaceuticals …
Two billion people still lack medicines access. Is the industry doing enough?
December 22, 2015Manufacturing and Production Access to Medicine Foundation, Access to Medicine Index, affordability, market access, medicines access, pricing
“We have a mission to encourage the pharmaceutical industry in improving access to medicine for the two billion people who …
EMA management board chair stands down
December 21, 2015Manufacturing and Production, Sales and Marketing EMA, European Medicines Agency, Sir Kent Woods
Sir Kent Woods will step down as chair of the board at the EMA from the end of December 2015. …
MSD’s Keytruda impresses in lung cancer chemotherapy trial
December 21, 2015Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab
MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …
Novartis completes purchase of rights to GSK drug for up to $1bn
December 21, 2015Manufacturing and Production, Research and Development, Sales and Marketing
Novartis has completed the acquisition of all outstanding rights to Arzerra from GSK for up to $1.034 billion. The deal, …
Experts predict pharma sector to remain strong in 2016
December 21, 2015Sales and Marketing marketing, pharma, profits, sales
The year 2016 is set to see continued growth in research and development productivity, with significant new drug launches and …
ISIS Pharma changes name to Ionis to avoid ‘distracting’ militant association
December 21, 2015Sales and Marketing Ionis, Isis Pharmaceuticals, branding, marketing, rebrand
After months of discussion, ISIS Pharmaceuticals has changed its name to Ionis to free itself from the fear of confusion …
Merck on the march in Africa
December 21, 2015Sales and Marketing Africa, Merck, marketing, sales, strategy
When Merck unveiled its Africa 2020 strategy in November, there was no shortage of ambition.The company announced plans to expand …
Three AstraZeneca drugs recommended by EMA committee
December 21, 2015Sales and Marketing AstraZeneca, Brilique, CHMP, EMA, Portrazza, Tagrisoo, lesinurad, lilly
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended several new drugs in its latest meeting, including …
Martin Shkreli resigns from Turing
December 21, 2015Sales and Marketing Martin Shkreli, Shkreli, Turing Pharmaceuticals
Following his arrest on securities fraud charges, Martin Shkreli has resigned as chief executive of Turing and been replaced by …
Ariad names EMD Serono’s Paris Panayiotopoulos as new president and chief exec
December 21, 2015Sales and Marketing Ariad, Ariad Pharmaceuticals, EMD Serono, Paris Panayiotopoulos, harvey Berger
The board of directors at Ariad Pharmaceuticals has appointed Paris Panayiotopoulos as president and chief executive from 1 January 2016. …
Gilead steps in to rescue Galapagos RA drug
December 18, 2015Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis
Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …
European approval for Amgen cancer drug Imlygic
December 18, 2015Sales and Marketing Amgen, European Commission, Imlygic, melanoma, skin cancer, t-vec, talimogene laherparepvec
The European Commission has approved the use of Amgen’s Imlygic for adults with advanced melanoma, making it the first drug …
Karma may have caught up with Martin Shkreli, but America’s drug pricing problem isn’t about one man
December 18, 2015Manufacturing and Production, Sales and Marketing Daraprim, Martin Shkreli, Turing Pharmaceuticals
As so often occurs in situations of this kind, Twitter reacted with a significant amount of glee and schadenfreude to …
Servier UK appoints new chief executive
December 18, 2015Manufacturing and Production, Research and Development, Sales and Marketing Arnaud Lallouette, Mike Sumpter, Servier
Dr Arnaud Lallouette has been appointed chief executive of Servier Laboratories, the UK subsidiary of the French-based pharma firm, after …
Horizon chief exec Walbert to head up US biotech trade body
December 18, 2015Manufacturing and Production, Research and Development, Sales and Marketing Illinois Biotechnology Industry Organisation, Timothy Walbert, iBio, illinois
Timothy Walbert, the chairman, president and chief executive of Horizon Pharma, has been elected as chairman of the board of …
ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs
December 18, 2015Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare
Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
